Analysis ITD Mutation Number,length And Level Influence On Prognosis In 130 Cases Of FLT3-ITD Positive Acute Myeloid Leukemia Patients

Objective: FLT3-ITD positive acute myeloid leukemia has been classified as high-risk group with poor prognosis. FLT3-ITD mutation occurred in various number, length and burden. The aim of this study is to analyze the relationship betwee n FLT3-ITD mutation(ITD mutation number, length and burden) and the overall survival and complete remission duration in AML(M3 excluded).Method: Genomic DNA was amplified by PCR, capillary electrophoresis was used to detect the FLT3-ITD characteristics. Single or multiple mutations were distinguished according to the number of peak. FLT3-ITD mutation burden is calculated with the method of peak area of mutant / wild-type and mutant peak areas. C linical data was collected and followed up if the patient with FLT3-ITD mutation had accepted treatment in our hospital.Result: Multiple FLT3-ITD mutations were common in patients a ged 60 and above. Patients with a single FLT3-ITD mutation had higher percentage of bone marrow blasts than that with multiple FLT3-ITD mutations(median 75.8%, 63.8%;P=0.028). The number of FLT3-ITD did not affect prognosis. The Length of FLT3-ITD did not affect prognosis. Patients with FLT3-ITD mutation burden <10% showed no difference with the intermediate-risk CKT+ group in OS and CRD, but both of these two groups had longer OS and CRD than those with FLT3-ITD mutation burden≥ 10%(median survival time undefined, undefined, 9.9 months, P<0.05;CRD median undefined, undefined, 6.7 months, P<0.05).In patients with FLT3-ITD mutation burden >10%, those along with NPM1 or CEBPA mutation had markedly longer CRD than those with FLT3-ITD mutation alone(median 25.0 months,5.1 months; P=0.003), while their OS were similar(median survival time 11.4 months,8.0 months;P>0.05). Conclusions Our results showed t hat in AML(M3 excluded), patients with FLT3-ITD mutation burden <10% had a better prognosis than those≥ 10%Conclusion: Our results showed that in AML(M3 excluded), patients with FLT3-ITD mutation burden <10% had a better prognosis than those ≥10% in our center.